Bifogade filer
Vicore Annual Report 2024
549300KTNBPTZLF01130
Kurs
-2,68%
Likviditet
1,45 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-27 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | N/A | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2025-05-06 | N/A | Årsstämma |
| 2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-05 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2019-05-15 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2019-01-07 | - | Extra Bolagsstämma 2018 |
| 2018-10-19 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-13 | - | Årsstämma |
| 2018-05-09 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-10-19 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-11 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2017-05-10 | - | Årsstämma |
| 2017-05-10 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-27 | - | Extra Bolagsstämma 2017 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2016-10-13 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-08 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-27 | - | Årsstämma |
| 2016-04-15 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, March 26, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2024.
The Annual Report for the financial year 2024 is available on the company’s website: https://vicorepharma.com/investors/financial-reports/
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com
This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-26 08:00 CET.